BiotechTube
Memgen

Memgen

Houston, United States· Est.
memgenbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Memgen is a private, clinical-stage biotech developing a proprietary viral immunotherapy platform for oncology. Its lead candidate, MEM-288, is an oncolytic adenovirus engineered to express CD40 ligand and interferon-beta (IFNβ), designed to prime a potent, tumor-targeted T-cell response. Preliminary Phase 1 data in advanced NSCLC shows promising clinical benefit and immune activation with a favorable safety profile. The company is led by a seasoned management team with strong scientific and financial expertise, supported by a distinguished scientific advisory board.

Oncology

Technology Platform

Proprietary oncolytic adenovirus platform engineered to express immune-stimulating transgenes (e.g., CD40 ligand and interferon-beta) to generate a systemic, tumor-targeted T-cell immune response.

Funding History

1
Series AUndisclosed

Opportunities

MEM-288 addresses the large unmet need in NSCLC patients who are refractory to checkpoint inhibitors.
The platform's mechanism supports potential for combination therapies and expansion into other solid tumor indications, offering significant market expansion opportunities.

Risk Factors

High clinical development risk as early data requires validation in larger trials.
The company is a single-asset, pre-revenue entity dependent on raising substantial capital.
It faces intense competition from established immunotherapies and novel modalities in oncology.

Competitive Landscape

Memgen competes in the crowded NSCLC immunotherapy space dominated by PD-1/L1 checkpoint inhibitors (e.g., Keytruda, Opdivo). Its viral vector approach competes with other oncolytic virus therapies like Imlygic (talimogene laherparepvec) and numerous clinical-stage candidates from companies such as Turnstone Biologics and Replimune.

More companies in Biologics / Biosimilars →More companies in United States →